COMP <GO>
CGEM vs INBX // EV/EBITDA & P/E VALUATION
Cullinan Therapeutics Inc. (NASDAQ) VS. Inhibrx Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: CGEM 1
— INBX 3
■ METRIC PARITY
LAST: $15.45 (-0.71%) • MKT CAP: $994.3M
valuation
—
LAST: $73.65 (+0.49%) • MKT CAP: $1.08B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEM VS. INBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEM | INBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.68% | -11.98% | -5.70 | INBX | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | INBX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 31.2 | +14.15 | CGEM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $994.3M | $1.08B | -$89.7M | INBX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEM REV | INBX REV | CGEM GROSS % | INBX GROSS % | CGEM FCF | INBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.3M | — | — | -$175.8M | -$129.8M |
| FY 2024 | $0 | $200.0K | — | — | -$145.3M | -$197.0M |
| FY 2023 | $0 | $1.8M | — | — | -$134.3M | -$193.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEM // BETA —
INBX // BETA —